Recludix Pharma has raised $123 million in equity financing, including a strategic investment from Eli Lilly, to expedite the development of its innovative SH2 domain inhibitors and enhance its drug discovery capabilities through a partnership with Lilly's AI platform.

Overview of Recludix Pharma

Recludix Pharma is a clinical-stage biotechnology company focused on the discovery and development of targeted inhibitors for complex inflammatory diseases. The company operates a distinctive drug discovery platform that utilizes custom-generated DNA-encoded libraries and sophisticated screening techniques to identify potent and selective inhibitors against challenging protein targets. With a leadership team composed of industry veterans from notable organizations such as Seagen, Blueprint Medicines, and Lilly, Recludix is well-positioned to advance its innovative therapeutic approaches, particularly in the development of SH2 domain inhibitors.

Currently, Recludix is managing a Phase 1 clinical trial of REX-8756 (SAR448755), an oral inhibitor aimed at targeting the abnormal activation of STAT6, which is implicated in several inflammatory conditions like atopic dermatitis, asthma, chronic obstructive pulmonary disease, and chronic spontaneous urticaria. Additionally, the company is exploring line of inquiry into a potential first-in-class BTK SH2 domain inhibitor tailored for B cell or mast cell-driven inflammatory and immune (I&I) diseases.

Industry Overview in the Biotechnology Sector

The biotechnology industry has experienced significant expansion in the United States, driven by advancements in research and technology that allow for the development of novel therapeutics. California, particularly San Diego, is a hub for bioph